Improving psychiatric drug benefit management: II. Kaiser Permanente's approach to SSRIs.
Sabin
James E
JE
Department of Ambulatory Care and Preventiom, Boston, Massachusetts 02215, USA. jim_sabin@hphc.org
Daniels
Norman
N
D017046:Cost Savings; D003866:Depressive Disorder / Q000188:drug therapy* / Q000191:economics*; D016527:Drug Costs / Q000706:statistics & numerical data*; D016568:Drugs, Generic / Q000191:economics* / Q000627:therapeutic use; D005473:Fluoxetine / Q000191:economics / Q000627:therapeutic use; D006279:Health Maintenance Organizations / Q000191:economics*; D006801:Humans; D007356:Insurance, Pharmaceutical Services / Q000191:economics*; D008329:Managed Care Programs / Q000191:economics*; D017367:Selective Serotonin Reuptake Inhibitors / Q000191:economics* / Q000627:therapeutic use; D014481:United States
D016568:Drugs, Generic; D005473:Fluoxetine; D017367:Selective Serotonin Reuptake Inhibitors